bioMérieux company profile
Company profile
bioMérieux has 14,562 employees and is headquartered in Marcy-l'Étoile, France.
Many clinicians and laboratories know bioMérieux through VITEK 2, BIOFIRE and VIDAS, the systems used to identify bacteria, test their resistance to antibiotics and detect infections. The range also includes BACT/ALERT blood culture instruments, the VITEK MS mass spectrometry platform and API identification strips. Beyond these instruments, the group supplies culture media, PCR tests for viral respiratory infections and detection kits for the food industry, along with lab consultancy and training. It sells in France, across Europe, Africa, the Middle East, the Americas and Asia Pacific.
In the fiscal year ended December 2025, bioMérieux reported revenue of 4.1 billion euros, up 2.3% from the previous year, and net income of 397.5 million euros. The company is headquartered in Marcy-l'Étoile, France, was founded in 1963 and employs 14,562 people.
Company facts
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- France
- Headquarters
- 376 Chemin De l’Orme, 69280, Marcy-l'Étoile
- Employees
- 14,562
- Chief executive
- Pierre Boulud
- Founded
- 1963
- Fiscal year
- January - December
- Listing
- BIM · Euronext Paris
- Currency
- EUR
- ISIN
- FR0013280286
- Website
- biomerieux.com
bioMérieux and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| bioMérieuxBIM | France | $11.82B | 14,562 | 16.0% | 23.4 |
| QiagenQIA | Germany | $10.23B | 5,400 | 26.7% | 28.5 |
| Eurofins ScientificERF | France | $16.03B | 65,000 | 14.1% | 29.6 |
| DiaSorinDIA | Italy | $4.21B | 3,212 | 22.3% | 28.6 |
| Lonza GroupLONN | Switzerland | $54.2B | 20,141 | 23.5% | 43.2 |
| DiagnostykaDIA | Poland | $1.27B | 8,645 | 14.9% | 20.2 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
